Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

zonisamide

- PMLiVE

Pfizer and Flynn accused of overcharging for epilepsy drug

UK watchdog investigating the firms over the millions of pounds spent on Epanutin

- PMLiVE

FDA approves world’s first 3D printed drug

Aprecia’s epilepsy treatment Spritam seen as the future of drug manufacturing

EISAI

Eisai to transfer US manufacturing campus to Biogen

Willhand over Research Triangle Park facility incapacity-sharing deal

EISAI

Eisai launches thyroid cancer therapy Lenvima in UK

The UK is its first European market, with wider EU roll out expected in coming months

- PMLiVE

Disappointment for pharma with new Cancer Drugs Fund list

Bayer the only firm to win a reprieve from the CDF drug cull

EISAI

Eisai to share clinical trial data via external website

Company aims to further promote transparency in the industry

National Institute for Health and Care Excellence NICE logo

UK market access issues put on hold during election

NICE appraisals and Cancer Drugs Fund appeals will not be undertaken until May

EISAI

Eisai to make 200 cuts to US operations

Japanese firm says the restructure will help it stay competitive

EISAI

Eisai’s thyroid cancer drug Lenvima nears EU approval

Positive recommendation by the CHMP could see the orphan drug used in Europe within three months

UK flag

Cancer Drugs Fund a ‘missed opportunity’, says MP

Chair of the Liberal Democrat health committee Paul Burstow says the CDF should have gone further

- PMLiVE

Merck and Eisai link up on anti-PD-1 combinations

Will test Keytruda with both Lenvima and Halaven 

- PMLiVE

UCB boosted by core medicines growth

Firm’s new chief executive 'excited' by his company’s next batch of medicines

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links